Voclosporin: First Approval

Voclosporin (Lupkynis(™)) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a...

Descripción completa

Detalles Bibliográficos
Autor principal: Heo, Young-A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010786/
https://www.ncbi.nlm.nih.gov/pubmed/33788181
http://dx.doi.org/10.1007/s40265-021-01488-z
_version_ 1783673126355206144
author Heo, Young-A
author_facet Heo, Young-A
author_sort Heo, Young-A
collection PubMed
description Voclosporin (Lupkynis(™)) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis.
format Online
Article
Text
id pubmed-8010786
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80107862021-03-31 Voclosporin: First Approval Heo, Young-A Drugs AdisInsight Report Voclosporin (Lupkynis(™)) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis. Springer International Publishing 2021-03-31 2021 /pmc/articles/PMC8010786/ /pubmed/33788181 http://dx.doi.org/10.1007/s40265-021-01488-z Text en © Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle AdisInsight Report
Heo, Young-A
Voclosporin: First Approval
title Voclosporin: First Approval
title_full Voclosporin: First Approval
title_fullStr Voclosporin: First Approval
title_full_unstemmed Voclosporin: First Approval
title_short Voclosporin: First Approval
title_sort voclosporin: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010786/
https://www.ncbi.nlm.nih.gov/pubmed/33788181
http://dx.doi.org/10.1007/s40265-021-01488-z
work_keys_str_mv AT heoyounga voclosporinfirstapproval

Ejemplares similares